Oncology (all articles)
M-A: Role of diet in colorectal cancer incidence
17 Feb, 2021 | 01:12h | UTC
Editorial: Bundled payment models in oncology
17 Feb, 2021 | 01:16h | UTCEditorial: Bundled Payment Models in Oncology: Learning to Think in New Ways – JCO Oncology Practice
Counterpoint: Oncology Care Model: A Herculean Effort With Fixable Fatal Flaws – JCO Oncology Practice
Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging
16 Feb, 2021 | 01:50h | UTCCommentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)
Commentary on Twitter
A handy infographic of our recently published research
Full paper is open access and free for all ???
?https://t.co/xDlz1A4kjR@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi pic.twitter.com/cEwSCv4NXy— Imperial Prostate (@IP_London) February 14, 2021
RCT: Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer
16 Feb, 2021 | 01:44h | UTCShort-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
15 Feb, 2021 | 00:36h | UTCLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021
RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
15 Feb, 2021 | 00:34h | UTCEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today
Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer
15 Feb, 2021 | 00:31h | UTCTransdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)
Near-equivalence in oncology: Generating evidence to support alternative cost-effective treatments
11 Feb, 2021 | 02:02h | UTC
Commentary on Twitter
Thoughtful piece with real implications for decreasing costs and improving access to cancer care – with particular relevance in low- and middle-resource settings although applicable in all settings. https://t.co/MkQx6Gzte4
— Julie Gralow (@jrgralow) February 10, 2021
Cost-effective analysis suggests incorporating baseline breast density at 40 years to determine the frequency of screening in women at average risk for breast cancer
10 Feb, 2021 | 01:37h | UTCIncorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer: A Cost-Effectiveness Analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries: Screening based on breast density at age 40 may reduce breast cancer mortality – ACP Internist AND Screening strategy based on baseline breast density at age 40 may be effective for reducing breast cancer mortality – American College of Physicians AND For Mammography: Baseline at 40 Makes Sense – Diagnostic Imaging
Commentary on Twitter
New research led by @TinaShihHSR of @MDAndersonNews found screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing #breastcancer mortality https://t.co/9f0P7CSCmD. pic.twitter.com/PemE8XVSqr
— Annals of Int Med (@AnnalsofIM) February 9, 2021
PET imaging reveals which breast cancer patients won’t respond to hormone therapy
10 Feb, 2021 | 01:09h | UTC
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women
10 Feb, 2021 | 01:07h | UTC
A population-based study of genes previously implicated in breast cancer
10 Feb, 2021 | 01:05h | UTCA Population-Based Study of Genes Previously Implicated in Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Intraoperative imaging technology to maximize extent of resection for glioma: a network meta‐analysis
8 Feb, 2021 | 20:11h | UTC
Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
7 Feb, 2021 | 20:55h | UTCManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)
Audio Clinical Review: Management of Immunotherapy-Related Toxicities
Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
7 Feb, 2021 | 20:47h | UTCCommentaries: Breast cancer tops lung cancer as most diagnosed cancer in the world, new report says – CNN AND Breast Cancer Tops Lung Cancer for No. 1 Diagnosis Worldwide – Diagnostic Imaging
Related: Breast cancer now most common form of cancer: WHO taking action – World Health Organization
Commentary on Twitter
For the first time, female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer in the world according to the latest @AmericanCancer & @IARCWHO report. https://t.co/SmX8czB4Wx #GlobalCancerStats?️#WorldCancerDay pic.twitter.com/IUMFkMUzx2
— CA: A Cancer Journal for Clinicians (@CAonline) February 4, 2021
Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer
7 Feb, 2021 | 20:45h | UTCCommentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive
RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer
5 Feb, 2021 | 01:27h | UTCCommentary: Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard – Ontario Institute for Cancer Research AND Another Win for MRI and Targeted Prostate Biopsy – MedPage Today (free registration required)
Related: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis – New England Journal of Medicine (study and commentaries) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis – European Urology AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer (studies and commentaries)
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
5 Feb, 2021 | 01:19h | UTC
Impact of COVID-19 on cancer care has been ‘profound’, warns UN health agency
5 Feb, 2021 | 01:38h | UTCImpact of COVID-19 on cancer care has been ‘profound’, warns UN health agency – UN News
Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer
3 Feb, 2021 | 01:10h | UTC
Meta-analysis: Risk of colorectal cancer and cancer related mortality after detection of low-risk or high-risk adenomas, compared with no adenoma, at index colonoscopy
3 Feb, 2021 | 01:20h | UTCRisk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review And Meta-Analysis – Gastroenterology (link to abstract – $ for full-text)
Related studies: Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies – Gastroenterology AND Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population – Gastroenterology (link to abstract – $ for full-text) AND Baseline Colonoscopy Findings Associated with 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance – Gastroenterology (link to abstract – $ for full-text) AND Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence – JAMA
Related guideline: Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer – Gastroenterology
Small study shows feasibility of MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer
3 Feb, 2021 | 01:09h | UTCCommentary: Study: MRI-guided ultrasound treats prostate cancer with few side effects – UPI